Research

Energy balance

Endoscopic sleeve gastroplasty (ESG) is more cost-effective than semaglutide over a 5-year time horizon, with an incremental cost-effectiveness ratio (ICER) of -$595,532/QALY.

Practitioners may consider ESG as a more cost-effective option for treating class II obesity compared to semaglutide.

StrongSupportsmedium confidence
The model found that ESG was more cost-effective than semaglutide over a 5-year time horizon, with an ICER of -$595 532/QALY.
Muhammad Haseeb et al. · JAMA Network Open · 2024

Why this rating

Based on the economic evaluation study design.

Source

Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss

Muhammad Haseeb et al. · JAMA Network Open · 2024

DOI 10.1001/jamanetworkopen.2024.6221

otherCited 66×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →